CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Lower Risk of Heart Failure and Death in Patients Initiated on SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study Percutaneous Atriotomy for Levoatrial–to–Coronary Sinus Shunting in Symptomatic Heart Failure: First-in-Human Experience Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes Left Ventricular Assist Device as a Bridge to Recovery for Patients With Advanced Heart Failure Sex Differences in Cardiovascular Pathophysiology: Why Women Are Overrepresented in Heart Failure With Preserved Ejection Fraction Left Ventricular Assist Devices for Lifelong Support 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL 2 Study

Original Research2019 May;21(5):665-675.

JOURNAL:Eur J Heart Fail. Article Link

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF)

McMurray JJV, DeMets DL, DAPA-HF Committees and Investigators. Keywords: protocol; heart failure; sodium-glucose co-transporter 2 inhibitor; type 2 diabetes mellitus

FULL TEXT PDF